Human Papillomavirus-Related Carcinoma, Human Papillomavirus-Related Cervical Carcinoma, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage II Vaginal Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA Vaginal Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIB Vaginal Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8
Conditions
Brief summary
This trial studies how well magnetic resonance imaging (MRI)-guided internal radiation therapy (brachytherapy) works in treating participants with human papillomavirus (HPV) associated stage IB2-IV cervical or stage II-IVA vaginal cancer. Using MRI guidance during brachytherapy applicator placement may improve treatment planning in participants with cervical or vaginal cancer.
Detailed description
PRIMARY OBJECTIVES: I. Determine whether MRI guidance during internal radiation therapy applicator placement improves the high-risk clinical target volume (HR-CTV) D90 (dose to 90% of the high-risk clinical target volume) rate compared to conventional guidance, with ultrasound and freehand technique, for patients with cervical and vaginal cancer. SECONDARY OBJECTIVES: I. Identify diffusion weighted MRI image features that can be used to identify sites of viable tumor following external beam radiotherapy as assessed by tumor aspirate cytology. II. Determine if diffusion weighted MRI findings are associated with immune infiltration as assessed by multi-spectral flow cytometry. III. Identify potential correlates between clinical outcomes (survival, progression) and these data objectives (brachytherapy dosimetry/therapeutic ratio, diffusion-weighted MRI imaging features, tumor aspirate cytology findings). IV. Define the financial costs and feasibility of an MRI-guided brachytherapy approach to determine the overall healthcare quality value (outcomes/cost) of this novel approach for application at other brachytherapy centers. OUTLINE: Participants undergo MRI scan during internal radiation therapy applicator placement.
Interventions
RADIATIONInternal Radiation Therapy
Undergo brachytherapy
PROCEDUREMagnetic Resonance Imaging
Undergo MRI scan
Sponsors
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women with stage 1B2-IVA cervical cancer recommended to receive definitive chemoradiation including brachytherapy; or * Women with stage II-IVA vaginal cancer recommended to receive definitive chemoradiation including brachytherapy.
Exclusion criteria
* Patient or tumor anatomy that requires use of a non-MRI-compatible applicator. * Patients with implantable cardioverter-defibrillator, pacemaker or other implanted device or medical condition which precludes MRI acquisition.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent of patients achieving high-risk clinical target volume (HR-CTV) dose to 90% (D90) | Up to 4 years | Rate will be compared to conventional guidance, with ultrasound and freehand technique. We will compare the HR-CTV D90 and other secondary dosimetry parameters (e.g. D2 cc bladder, D2 cc rectum etc.) between the initial scan (subsequent to ultrasound \[US\] guided or freehand applicator placement) and optimized (with magnetic resonance imaging \[MRI\] guided placement) treatment plan for each patient using McNemar's test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Biomarker measurements (tumor viability and tumor T cell profile) from tumor samples | Up to 4 years | A paired t-test will be used to compare apparent diffusion coefficient (ADC) areas for each biomarker. |
| Disease recurrence (local, regional, and distant) | Up to 4 years | determined via axial imaging (MRI or PET/CT) on interval follow-up |
| Overall survival | Up to 4 years | — |
| Diffusion weighted imaging (DWI) outcomes | Up to 4 years | — |
| Incidence and severity of treatment-related toxicities | Up to 4 years | as defined via CTCAE v4.0 |
| Cost difference associated with the MRI-guided versus the standard process | Up to 4 years | Billing and financial data will be calculated and compared to that of the conventional non-MRI-guided brachytherapy approach. |
| Progression-free survival | Up to 4 years | — |
Countries
United States
Outcome results
None listed